Sumida, Hitoshi
Yasunaga, Yuichi
Takasawa, Kensei
Tanaka, Aya
Ida, Seiko
Saito, Tadaoki
Sugiyama, Seigo
Matsui, Kunihiko
Nakao, Koichi
Tsujita, Kenichi
Tohya, Yuji
Article History
Received: 28 October 2019
Accepted: 24 January 2020
First Online: 12 February 2020
Compliance with ethical standards
:
: Dr. Tsujita has received honoraria from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co. Ltd., MSD K.K., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd.; has received trust research/joint research funds from AstraZeneca K.K., Sugi Bee Garden, and Japan Medical Device Technology Co., Ltd.; and has received grants from ITI Co., Ltd., Astellas Pharma Inc, Abbott Vascular Japan Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kaneka Medix Co., Ltd., Goodman Co., Ltd., GM Medical Co., Ltd., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co., Ltd., TERUMO Co., Ltd., Boehringer Ingelheim Japan, Medtronic Japan Co., Ltd., Japan Lifeline Co., Ltd., Novartis Pharma K.K., Fides-One, Inc., Bristol-Myers K.K., Boston Scientific Japan K.K., Cardinal Health Japan, and MSD K.K. Dr. Sugiyama is on the Speaker’s Bureau of MSD, Inc., and AstraZeneca Pharmaceuticals LP, Ono Pharmaceutical CO., LTD, and Bayer Yakuhin Ltd.